Siplizumab
| Siplizumab | |
|---|---|
| Term | Siplizumab |
| Short definition | Siplizumab - (pronounced) (sip-LIH-zoo-mab) substance being studied to treat certain types of T-cell lymphoma. It is also being studied to prevent organ or tissue rejection after kidney and/or bone marrow transplants. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Siplizumab - (pronounced) (sip-LIH-zoo-mab) substance being studied to treat certain types of T-cell lymphoma. It is also being studied to prevent organ or tissue rejection after kidney and/or bone marrow transplants. Siplizumab attaches to a protein called CD2, which is found on some types of immune cells and cancer cells. This can help suppress the body's immune response and kill cancer cells. Siplizumab is a type of monoclonal antibody. Also called MEDI-507
External links
- Medical encyclopedia article on Siplizumab
- Wikipedia's article - Siplizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski